Advertisement

Medical Oncology

, Volume 12, Issue 3, pp 187–201 | Cite as

How to optimize the effect of 5-fluorouracil modulated therapy in advanced colorectal cancer

  • Peter Ragnhammar
  • Henric Blomgren
Article

Keywords

5-fluorouracil colorectal carcinoma 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Silverberg, E., Boring, C.C. and Squires, T.S. (1990)Cancer Statistics CA 40, 9–26.Google Scholar
  2. 2.
    Higgins, G.A. (1983) Current status of adjuvant therapy in the treatment of large bowel cancer.Surg. Clin. North. Am. 63, 37–50.Google Scholar
  3. 3.
    Stockholm Rectal Cancer Study Group (1990) Preoperative short-term radiation therapy in operable rectal carcinoma. A prospective randomized trial.Cancer 66, 49–55.Google Scholar
  4. 4.
    Jansson-Frykholm, G.J., Glimelius, B. and Påhlman, L. (1993) Preoperative and postoperative irradiation in adenocarcinoma randomized trial and an evaluation of late secondary effects.Dis. Colon Rectum 36, 564–72.Google Scholar
  5. 5.
    Abbruzzese, J.L. and Levin, B. (1989) Treatment of advanced colorectal cancer.Hematology/Oncology Clinics of North America 3, 135–53.PubMedGoogle Scholar
  6. 6.
    Davis, H.L. (1982) Chemotherapy of large bowel cancer.Cancer 50, 2638–46.PubMedGoogle Scholar
  7. 7.
    Lavin, P., Mittelman, A., Douglas, H., Engström, P. and Klassen, D. (1980) Survival and responses to chemotherapy for advanced colorectal carcinoma.Cancer 46, 1536–43.PubMedGoogle Scholar
  8. 8.
    Pinedo, H.M. and Peters, G.J. (1988) Fluorouracil: biochemistry and pharmacology.J. Clin. Oncol. 6, 1653–64.PubMedGoogle Scholar
  9. 9.
    The Nordic Gastrointestinal Cancer Adjuvant Therapy Group (1993) Biochemical modulation of 5-fluorouracil: a randomized comparison of sequential methotrexate, 5-fluorouracil and leucovorin versus sequential 5-fluorouracil and leucovorin in patients with advanced symptomatic colorectal cancer.Ann. Oncol. 4, 235–40.Google Scholar
  10. 10.
    The Nordic Gastrointestinal Tumor AdJuvant Therapy Group (1989) Superiority of sequential methotrexate, fluorouracil and leucovorin to fluorouracil alone in advanced symptomatic colorectal carcinoma: a randomized trial.J. Clin. Oncol. 7, 1437–46.Google Scholar
  11. 11.
    Moertel, C.G., Fleming, T.R., MacDonald, J.S.et al. (1990) Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma.N. Engl. J. Med. 322, 352–8.PubMedGoogle Scholar
  12. 12.
    Frösing, R. (1994) Mechanisms of interaction between thymidylate synthase and 5-fluorouracil in human tumors. Dissertation, University of Gothenburg, Sweden.Google Scholar
  13. 13.
    Seifert, P., Baker, D.O., Reed, M.D., Laurence, H., Melvin, L. and Vaitkevicius, V.K. (1975) Comparison of continuously infused 5-fluorouracil with bolus injections in treatment of patients with colorectal adenocarcinoma.Cancer 36, 123–8.PubMedGoogle Scholar
  14. 14.
    Lokich, J.J., Ahlgren, J.D., Gullo, J.J., Philips, J.A. and Fryer, J.G. (1989) A prospective randomized comparison of continuous infusion with a conventional bolus schedule in metastatic colorectal carcinoma: A Mid-Atlantic Oncology Program Study.J. Clin. Oncol. 7, 425–32.PubMedGoogle Scholar
  15. 15.
    Weinerman, B., Shah, A., Fields, A., Kerr, I., Cripps, C., Shepherd, F., Wilson, K., McCormick, R., Temple, W., Maroun, J., Bogues, W. and Pater, J. (1992) A randomized trial of continuous systemic infusion (SI)vs bolus therapy (B) with 5-fluorouracil (5-FU) in metastatic measurable colorectal cancer (MCC).Am. J. Clin. Oncol. Dec. 15 (6), 518–23.Google Scholar
  16. 16.
    Leichman, C.G., Fleming, F.M., Muggia, B., Ardalan, J., Doroshow, C., Tangen, C. and MacDonald, J. (1993) Fluorouracil (5-FU) schedules and modulation in advanced colorectal cancer (CRC): A Southwest Oncology Group (SWOG) screening trial.Proc. Am. Soc. Clin. Oncol. 12, 583.Google Scholar
  17. 17.
    Allegra, C., Lippman, M.E., Chabner, B.A.et al. (1988) The salvage treatment of patients with metastatic breast cancer with 5-fluorouracil and leucovorin. In:The expanding role of folates and fluoropyrimidines in cancer chemotherapy, an International Symposium. April 28–9, Roswell Park Memorial Institute, Buffalo, NY (Abstract).Google Scholar
  18. 18.
    Houghton, J.A., Maroda, J.J. Jr, Phillips, J.O. and Houghton, P.J. (1981) Biochemical determinants of responsiveness to 5-fluorouracil and its derivatives in xenografts of human colorectal adenocarcinoma in mice.Cancer Res. 41, 144–9.PubMedGoogle Scholar
  19. 19.
    Rustum, Y.M., Madajewicz, S., Cambell, J.et al. (1984) Clinical, biochemical pharmacology of 5-formyltetrahydrofolate in combination with 5-fluorouracil in patients with advanced colorectal carcinoma: Correlation with clinical response. In H.W. Bruckner and Y. Rustum, (eds)The current status of 5-fluorouracil-leucovorin combination, p. 77–85. New York: Park Row.Google Scholar
  20. 20.
    Evans, R.M., Laskin, J.D. and Hakala, M.T. (1981) Effect of excess folates and deoxylnosine on the activity and site of action of 5-fluorouracil.Cancer Res. 41, 3288–95.PubMedGoogle Scholar
  21. 21.
    Kuhl, M., Jauch, K., Engemann, B., Riedelsheimer, C., Schalhorn, A. and Wilmanns, W. (1994) Tissue levels of 5,10-methylenetetrahydrofolate and tetrahydrofolate in patients with colorectal carcinoma with or without preoperative treatment with folinic acid or 5-methyltetrahydrofolate.Proc. Am. Soc. Clin. Oncol. (Meeting, Abstract).Google Scholar
  22. 22.
    Bruckner, H.W., Glass, L.L. and Chesser, M.R. (1990) Dose-dependent leucovorin efficacy with an intermittent high dose 5-fluorouracil schedule.Cancer Invest. 8, 315–20.Google Scholar
  23. 23.
    Bruckner, H.W., Roboz, J. and Ambinder, E. (1984) An efficient leucovorin-5-fluorouracil sequence: Dosage escalation and pharmacological monitoring. In: H.W. Bruckner and Y.M. Rustum (eds)The current status of 5-fluorouracilleucovorin calcium combination, pp. 65–8. New York, NY, Park Row.Google Scholar
  24. 24.
    Rougier, P., Droz, J.P., Ducreux, M., Kac, J., Spielmann, M., Crespon, B., Ley, G., Zimmerman, P., Theodore, C., Chavy, A.et al. (1983) Treatment of advanced colonic and rectal adenocarcinoma: Combination of 5-FU and high-dose folinic acid.Bull. Cancer (Paris) 70 (5), 434–6.Google Scholar
  25. 25.
    De Gramont, A., Krulik, M., Cady, J., Lagadec, B., Maisani, J.-E., Loiseau, J.-P., Grange, J.-D., Gonzalez-Canali, G., Demuynck, B., Louvet, C., Seroka, J., Dray, C. and Debray, J. (1988) High-dose folinic acid and 5-fluorouracil bolus and continuous infusion in advanced colorectal cancer.Eur. J. Cancer Clin. Oncol. 24, 1499–1503.PubMedGoogle Scholar
  26. 26.
    Byrne, P.J., Treat, J. and McFadden, M. (1984) Therapeutic efficacy of the combination of 5-fluorouracil and high-dose leucovorin in patients with advanced colorectal carcinoma: Single daily intravenous dose for five days. In H.W. Bruckner and Y.M. Rustum (eds)The Current Status of 5-fluorouracil-Leucovorin Calcium Combination. New York, NY, Park Row, pp. 65–8.Google Scholar
  27. 27.
    Wilke, H., Schmoll, H.J., Schober, C.et al. (1980) Folinic acid (FA) plus 5-fluorouracil (5-FU) in progressive advanced colorectal cancer.Biomed. Pharmacother. 42, 373–80.Google Scholar
  28. 28.
    Hines, J.D., Adelstein, D.J., Spiess, J.L., Giroski, P. and Gear Carter, S. (1989) Efficacy of high-dose oral leucovorin and 5-fluorouracil in advanced colorectal carcinoma. Plasma and tissue pharmacokinetics.Cancer 63, 1022–5.PubMedGoogle Scholar
  29. 29.
    Cunningham, J., Bukowski, R.M., Budd, G.T., Weick, J.K. and Purvis, J. (1984) 5-fluorouracil and folinic acid: A phase I–II trial in gastrointestinal malignancy.Invest. New Drugs. 2, 391–5.PubMedGoogle Scholar
  30. 30.
    DiCostanzo, F., Bartolucci, R., Padalino, D., Brugia, M. and Buzzi, F. (1988) High-dose folinic acid and 5-fluorouracil in advanced colorectal cancer.Cancer Invest. 6, 133–8.Google Scholar
  31. 31.
    Machover, D. (1988) Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil and high-dose folinic acid.2nd Int. Congr. on Neo-Adj Chemother. p. 70. February 19–21, Paris.Google Scholar
  32. 32.
    Madajewicz, S., Petrelli, N., Rustum, Y.M., Campbell, J., Herrera, L., Mittelman, A., Perry, A. and Creaven, P.J. (1984) Phase I–II trial of high-dose calcium leucovorin and 5-fluorouracil in advanced colorectal cancer.Cancer Res. 44, 4667–9.PubMedGoogle Scholar
  33. 33.
    Schöber, C.H., Köhne-Wömpner, C.H., Schmoll, H.J., Stahl, M., Wilke, H.J. and Poliwoda, H. (1992) A 3-day schedule of 5-fluorouracil and folinic acid in metastatic progressive colorectal cancer and its impact in terms of palliation.Semin. Oncol. 2, 136–40.Google Scholar
  34. 34.
    Tempero, M., Berg, A., Block, M., Hutchins, M., Moravec, D. and Langdon, R. (1993) A phase II trial of protracted therapy with 5-fluorouracil and leucovorin in metastatic colorectal cancer.Proc. Am. Soc. Clin. Oncol. 12, 594.Google Scholar
  35. 35.
    Doroshow, J.H., Multhauf, P., Leong, L., Margolin, K., Litchfield, T., Akman, S., Carr, B., Bertrand, M., Goldberg, D., Blayney, D., Odujinrin, O., DeLap, R., Shuster, J. and Newman, E. (1990) Prospective randomized comparison of fluorouracil vs fluorouracil and high-dose continuous infusion leucovorin calcium for the treatment of advanced measurable colorectal cancer in patients previously unexposed to chemotherapy.J. Clin. Oncol. 8, 491–501.PubMedGoogle Scholar
  36. 36.
    Di Constanzo, F., Bartolucci, R., Calabresi, R., Sofra, M., Marzola, M., Belsanti, V., Boni, C. and Bacchi, M. (1992) Fluorouracil alone versus high-dose folinic acid and fluorouracil in advanced colorectal cancer: A randomized trial of the Italian Oncology Group for Clinical Research.Ann. Oncol. 3, 371–6.Google Scholar
  37. 37.
    Valone, F.H., Friedman, M.A., Wittlinger, P.S., Drakes, T., Eisenberg, P.D., Malec, M., Hannigan, J.F. and Brown, B.W. Jr. (1989) Treatment of patients with advanced colorectal carcinomas with fluorouracil alone, high-dose leucovorin plus fluorouracil or sequential methotrexate, fluorouracil and leucovorin. A randomized trial of the Northern California Oncology Group.J. Clin. Oncol. 7, 1427–36.PubMedGoogle Scholar
  38. 38.
    Labianca, R., Pancera, G., Beretta, G., Aitini, E., Barni, S., Beretta, G.D., Cesana, B., Comella, G., Cozzaglio, L., Cristoni, M.et al. (1991) A randomized study of intravenous fluorouracil +/- folinic acid in advanced metastatic colorectal carcinoma.Ann. Oncol. Oct. 2, 673–9.Google Scholar
  39. 39.
    Poon, M.A., O’Connel, M.J., Moertel, C.G., Wieand, H.S., Cullinan, S.A., Everson, L.K., Krook, J.E., Mailliard, J.A., Laurie, J.A., Tschetter, L.K. and Wiesenfeld, M. (1989) Biochemical modulation of fluorouracil: Evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma.J. Clin. Oncol. 7, 1407–18.PubMedGoogle Scholar
  40. 40.
    Poon, M.A., O’Connell, M.J., Wieand, H.S., Krook, C.G., Gerstner, J.B., Tschetter, L.K., Levitt, R., Kardinal, C.G. and Mailliard, J.A. (1991) Biochemical modulation of fluorouracil with leucovorin: Confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer.J. Clin. Oncol. 9, 1967–72.PubMedGoogle Scholar
  41. 41.
    Erlichman, C., Fine, S., Wong, A. and Elhakim, T. (1988) A randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma.J. Clin. Oncol. 6, 469–75.PubMedGoogle Scholar
  42. 42.
    Löffler, T., Korsten, F.W., Burghardt, F., Reis, H.E., Aulbert, E., Lindemann, W., Schröder, M., Hausamen, T.U., Strohmeyer, G. and Planker, H.E. (1992) Randomized comparison of 5-FU vs 5-FU median dose leucovorin in metastatic colorectal cancer.Dtsch. Med. Wochenschr. 117 (26), 1007–13.PubMedCrossRefGoogle Scholar
  43. 43.
    Nobile, M.T., Vidili, M.G., Sobrero, A., Rosso, R., Sertoli, M.R., Rubagotti, A., Guglielmi, A., Venturini, M., Canobbio, L., Fassio, T. and Gallo, L. (1992) 5-fluorouracil alone or combined with high dose folinic acid in advanced colorectal cancer patients: A randomized trial.Eur. J. Cancer 28A (11), 1823–7.PubMedGoogle Scholar
  44. 44.
    Petrelli, N., Herrera, L., Rustum, Y., Burke, P., Creaven, P., Stulc, J., Emrich, L.J. and Mittelman, A. (1987) A prospective randomized trial of 5-fluorouracil vs 5-fluorouracil and high-dose leucovorin vs 5-fluorouracil and high-dose leucovorin vs 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma.J. Clin. Oncol. 5, 1559–65.PubMedGoogle Scholar
  45. 45.
    Steinke, B., Gunther, E., Hirscmann, W.D.et al. (1991) Fluorouracil versus folinic acid/fluorouracil in advanced colorectal cancer — preliminary results of a randomized trial.Semin. Oncol. 18 (suppl. 8), 141–7.Google Scholar
  46. 46.
    Petrelli, N., Douglass, H.O.J., Herrera, L., Russell, D., Stablein, D.M., Bruckner, H.W., Mayer, R.J., Schinella, R., Green, M.D., Muggia, F.M., Megibow, A., Greenwald, E.S., Bukowski, R.M., Harris, J., Levin, B., Gaynor, E., Loutfi, A., Kalser, M.H., Barking, J.S., Benedetto, P., Woolley, P.V., Nauta, R., Weaver, D.W. and Leichman, L.P. (1989) The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: A prospective randomized phase III trial. Gastrointestinal Tumor Study Group.J. Clin. Oncol. 7, 1419–26.PubMedGoogle Scholar
  47. 47.
    O’Connel, M.J. (1989) A phase III trial of 5-fluorouracil and leucovorin in the treatment of advanced colorectal cancer.Cancer 63, 1026–30.Google Scholar
  48. 48.
    Martoni, A., Cricca, A., Guaraldi, M., Covizzi, M., Farris, A. and Pannuti, F. (1992) Weekly regimen of 5-FUvs 5-FU + intermediate dose folinic acid in the treatment of advanced colorectal cancer.Anticancer Res. 12, 607–12.PubMedGoogle Scholar
  49. 49.
    Jäger, E., Klein, O., Bernhard, H., Wächter, B., Heike, M., Dippoid, W., Meyer zum Buschenfelde, K.-H. and Knuth, A. (1994) Weekly high-dose folinic acid (FA)/5-fluorouracil (FU) vs low dose FA/FU in advanced colorectal cancer. Results of a randomized multicenter trial.Proc. Am. Soc. Clin. Oncol. 13, 556.Google Scholar
  50. 50.
    Brohée, D. (1991) 5-fluorouracil (5FU) with or without folinic acid (LV) in human colorectal cancer? Multivariate meta-analysis of the literature.Med. Oncol. Tumor. Pharmacother. 8, 271–80.PubMedGoogle Scholar
  51. 51.
    Advanced Colorectal Cancer Meta-Analysis Project (1992) Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate.J. Clin. Oncol. 10, 896–903.Google Scholar
  52. 52.
    Piedbois, P. and Buyse, M. (1993) What can we learn from a meta-analysis of trials testing the modulation of 5-FU by leucovorin?Ann. Oncol. 4, 15–9.PubMedGoogle Scholar
  53. 53.
    Cadman, E., Heimer, R. and Davis, L. (1979) Enhanced 5-fluorouracil nucleotide formation after methotrexate administration: explanation for drug synergism.Science 205 (4411), 1135–7.PubMedGoogle Scholar
  54. 54.
    Sullivan, R.D.E., Miller, W.Z., Zurek, R.A. and Ojima, Y. (1969) Reevaluation of methotrexate as an anticancer drug.Surg. Gynecol. Obstet. 125, 819–24.Google Scholar
  55. 55.
    Herman, R., Knuth, A.M. and Kleeberg, U. (1986) Randomized multicenter trial of sequential methotrexate (MTX) and 5-fluorouracil (FU) vs FU alone in metastatic colorectal carcinomas (CRC).Proc. Am. Soc. Clin. Oncol. 5, 91.Google Scholar
  56. 56.
    Marsh, J.C., Bertino, J.R., Rome, L.S.et al. (1989) Sequential methotrexate, 5-fluorouracil and leucovorin in metastatic colorectal cancer: A controlled comparison of two intervals between drug administration.Proc. Am. Soc. Clin. Oncol. 8, 103.Google Scholar
  57. 57.
    Wasternack, C. (1980) Degradation of pyrimidines and pyrimidine analogs — pathways and mutual influences.Pharmacol. Ther. 8, 629–51.PubMedGoogle Scholar
  58. 58.
    Gewert, D.S., Moore, G. and Clemens, M.J. (1983) Inhibition of cell division by interferons: The relationship between changes in utilization of thymidine for DNA synthesis and control of proliferation in Daudi cells.Biochem. J. 214, 983–90.PubMedGoogle Scholar
  59. 59.
    Barankiewicz, J., Kaplinsky, C. and Cohen, A. (1986) Modification of ribonucleotide and deoxyribonucleotide metabolism in interferon treated B-lymphoblastoid cells.J. Interferon Res. 6, 717–27.PubMedGoogle Scholar
  60. 60.
    Elias, L. and Sandoval, J.M. (1989) Interferon effects upon fluouracil metabolism by HL-60 cells.Biochem. Biophys. Res. Commun. 163, 867–74.PubMedGoogle Scholar
  61. 61.
    Elias, L. and Crissman, H.A. (1988) Interferon effects upon the adenocarcinoma 38 and H1-60 cell lines: Antiproliferative responses and synergistic interactions with halogenated pyrimidine antimetabolites.Cancer 48, 4868–73.Google Scholar
  62. 62.
    Schwartz, E.L., Babtiste, N., O’Connor, C.J., Wadler, S. and Otter, B.A. (1994) Potentiation of the antitumor activity of 5-fluorouracil in colon carcinoma cells by the combination of interferon and deoxyribonucleosides results from complementary effects on thymidine phosphorylase.Cancer Res. 54, 1472–8.PubMedGoogle Scholar
  63. 63.
    Wadler, S. and Schwartz, E.L. (1990) Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: A review.Cancer Res. 50, 3473–86.PubMedGoogle Scholar
  64. 64.
    Grem, J.L., Chu, E., Boarman, D., Balis, F.M., Murphy, R.F., McAtee, N. and Allegra, C.J. (1992) Biochemical modulation of fluorouracil with leucovorin and interferon: preclinical and clinical investigations.Semin. Oncol. 19, 36–44.PubMedGoogle Scholar
  65. 65.
    Lindley, C., Bernard, S., Gavigan, M.et al. (1990) Interferon-alpha increases 5-fluorouracil (5-FU) plasma levels 64-fold within one hour: Results of a phase I study.J. Interferon. Res. 10 (Suppl I), 132.Google Scholar
  66. 66.
    Danhauser, L., Gilchrist, T.L., Freimann, J.H.,et al. (1991) Effect of recombinant interferon-alpha2b on the plasma pharmacokinetics of fluorouracil in patients with advanced cancer.Proc. Am. Assoc. Cancer Res. 32, 17 (Abstr).Google Scholar
  67. 67.
    Schuller, J., Czeija, M., Micksche, M., Schernthaner, G., Fogl, U. and Jäger, W. (1992) Influence of interferon-alpha2b (IFN) ± leucovorin (LV) on pharmacokinetics (PK) of 5-fluorouracil.Semin. Oncol. 2 (Suppl 3), 93–7.Google Scholar
  68. 68.
    Yee, L.K., Allegra, C.J., Steinberg, S.M. and Grem, J.L. (1992) Decreased catabolism of 5-fluorouracil in peripheral blood mononuclear cells during combination therapy with fluorouracil, leucovorin, and interferon alfa-2a.J. Natl. Cancer Inst. 84, 1820–5.PubMedGoogle Scholar
  69. 69.
    Seymour, M.T., Patel, N., Johnston, A., Joel, S.P. and Slevin, M.L. (1994) Lack of effect of interferon alpha2a upon fluorouracil pharmacokinetics.Br. J. Cancer 70, 724–8.PubMedGoogle Scholar
  70. 70.
    Danhauser, L.L., Freimann, J.H., Gilchrist, T.L., Gutterman, J.U., Hunter, C.Y., Yeomans, A.C. and Markowitz, A.B. (1993) Phase I and plasma pharmacokinetic study of infusional fluorouracil combined with recombinant interferon alpha-2b in patients with advanced cancer.J. Clin. Oncol. 11, 751–61.PubMedGoogle Scholar
  71. 71.
    Pittman, K., Perren, T., Ward, N., Primrose, J., Slevin, M., Patel, N. and Selby, P. (1993) Pharmacokinetics of 5-fluorouracil in colorectal cancer patients receiving interferons.Ann. Oncol. 4, 515–6.PubMedGoogle Scholar
  72. 72.
    Einhorn, S., Blomgren, H., Jarstrand, C. and Strander, H. (1981) Influence of interferon on the immune system. In C. Steffen and H. Ludwig (eds),Clinical Immunology and Allergology, pp. 219–24. Biomedical Press.Google Scholar
  73. 73.
    Neefe, J.R. and John, W. (1991) Mechanism of interaction of interferon and 5-fluorouracil in solid tumors.Sem. Oncol. 18, 77–82.Google Scholar
  74. 74.
    Lundell, G., Blomgren, H., Cedermark, B., Silfverswärd, C., Theve, T. and Öhman, U. (1984) High-dose rDNA human alpha2 interferon therapy in patients with advanced colorectal adenocarcinoma: A phase II study.Radiother. Oncol. 1, 325–32.PubMedGoogle Scholar
  75. 75.
    Clark, P.I., Slevin, M.L., Reznek, R.H., Niederle, N., Kurschel, E., Lundell, G., Cedermark, B., Fallenius, A., Blomgren, H., Öhman, U., Silfverswärd, C., Theve, T. and Wrigley, P.F.M. (1987) Two randomized phase II trials of intermittent intravenous vs subcutaneous alpha2 interferon alone (trial 1) and in combination with 5-fluorouracil (trial 2) in advanced colorectal cancer.Int. J. Colorectal. Dis. 2, 26–9.PubMedGoogle Scholar
  76. 76.
    Wadler, S., Schwartz, E.L., Goldman, M., Lyver, A., Rader, M., Zimmerman, M., Itri, L., Weinberg, V. and Wiernik, P.H. (1989) Fluorouracil and recombinant alpha-2a-interferon: An active regimen against advanced colorectal carcinoma.J. Clin. Oncol. 7, 1769–75.PubMedGoogle Scholar
  77. 77.
    Wadler, S. and Wiernick, P.H. (1990) Clinical update on the role of fluorouracil and recombinant interferon alfa-2a in the treatment of colorectal carcinoma.Semin. Oncol. 17, 16–21.PubMedGoogle Scholar
  78. 78.
    Weh, H.J., Platz, D., Braumann, D., Buggisch, P., Eckardt, N., Schmiegel, W.H., Drescher, S., Kleeberg, U.R., Mullerleile, U. and Crone-Munzebrock, W. (1992) Phase II trial of 5-fluorouracil and recombinant interferon alfa-2b in metastatic colorectal carcinoma.Eur. J. Cancer 28A, 1820–3.PubMedGoogle Scholar
  79. 79.
    Pazdur, R., Bready, B. and Moore, D.F. (1991) Clinical trials of fluorouracil with alpha-interferon in advanced colorectal carcinoma.Semin. Oncol. 18, 67–70.PubMedGoogle Scholar
  80. 80.
    Hansen, R., Ritch, P., Libnock, J. and Anderson, T. (1991) Continuous 5-fluorouracil infusion and alpha interferon in advanced cancers: A report of initial treatment results.Am. J. Med. Sci. 301, 246–9.PubMedGoogle Scholar
  81. 81.
    Fornasiero, A., Daniele, O., Ghiotto, C., Aversa, S.M., Morandi, P. and Fiorentino, M.V. (1990) Alpha-2 interferon and 5-fluorouracil in advanced colorectal cancer.Tumori 76, 385–8.PubMedGoogle Scholar
  82. 82.
    Kemeny, N., Younes, A., Seiter, K., Kelsen, D., Sammarco, P., Adams, L., Derby, S., Murray, P. and Houston, C. (1990) Interferon alpha-2a and 5-fluorouracil for advanced colorectal carcinoma.Cancer 66, 2470–5.PubMedGoogle Scholar
  83. 83.
    Rubio, D., Jimeno, J., Camps, C., Aranda, E., Massuti, B., Blanco, E., Anton, A., Lizon, J. and Gonzalez-Larriba, J.L. (1992) Treatment of advanced colorectal cancer with recombinant interferon alpha and fluorouracil: Activity in liver metastasis.Clin. Invest. 10, 259–64.Google Scholar
  84. 84.
    Huberman, M., McClay, E., Atkins, M., Goldsweig, H., Bonanno, D., Layton, M. and Tessitore, J. (1991) Phase II trial of 5-fluorouracil (5-FU) and recombinant interferon-alpha-2a (IFN) in advanced colorectal cancer.Proc. Am. Soc. Clin. Oncol. 10, 478.Google Scholar
  85. 85.
    Douillard, J.Y., Leborgne, J., Danielou, J.Y., Lehur, P.A., Potiron, L., Le Neel, J.C., Bolze, J.L. and Jutel, P. (1991) Phase II trial of 5-fluorouracil (5-FU) and recombinant alpha-interferon (R alpha-IFN) (Intron A) in metastatic, previously untreated colorectal cancer (CRC).Proc. Am. Soc. Clin. Oncol. 10, 422.Google Scholar
  86. 86.
    Ragnhammar, P., Blomgren, H., Edler, D., Lundell, G., Magnusson, I. and Sonnenfeld, T. (1995) Different dose regimens of 5-fluorouracil and IFN-alpha in patients with metastatic colorectal carcinoma.Eur. J. Cancer 31A, 315–20.PubMedGoogle Scholar
  87. 87.
    John, W.J., Neefe, R.J., McDonald, J.S., Cantrell, J. and Smith, M. (1993) 5-fluorouracil and interferon-alpha-2a in advanced colorectal cancer. Results of two treatment schedules.Cancer 72, 3191–5.PubMedGoogle Scholar
  88. 88.
    York, M., Greco, F.A., Figlin, R.A., Einhorn, L., Man, T., Cockey, L., Mott, D. and Light, S.E. (1993) A randomized phase III trial comparing 5-FU with or without interferon ALFA 2a for advanced colorectal cancer.Proc. Am. Soc. Clin. Oncol. 12, 590.Google Scholar
  89. 89.
    Cellerino, R., Antognoli, S., Giustini, L., Acito, L. and Marcellino, M.et al. (1994) A randomized study of fluorouracil (5-FU) with or without alpha-interferon (IFN) in advanced colorectal cancer.Proc. Am. Soc. Clin. Oncol. (abstr.)13, 654.Google Scholar
  90. 90.
    Kocha, W. (1993) (Corfu-A Collaborative Group): 5-FU plus interferon alpha 2a vs 5-FU + leucovorin in metastatic CRC — results of a multicentre multinational phase III study.Proc. Am. Soc. Clin. Oncol. 12, 562.Google Scholar
  91. 91.
    Brunetti, I., Falcone, A., Bertuccelli, M., Giannessi, P.G., Conte, P.F., Cianci, C. and Ricci, S. (1994) Double 5-fluorouracil (5-FU) modulation with folinic acid (FA) and recombinant alfa 2-B interferon (IFN) in patients (PTS) with metastatic colorectal carcinoma (MCRC).Am. J. Clin. Oncol. 3, 210–4.CrossRefGoogle Scholar
  92. 92.
    Labianca, R., Giaccon, G., Pancera, G., Ambrosini, G., Amichetti, G., Barni, S., Cascinu, S., Martignoni, G., Pavaaanato, G., Scapaticci, R., Zaniboni, A. and Luporini, G. (1992) Low dose alfa2b interferon (IFN) + folinic acid (FA) + 5-fluorouracil (5FU) in advanced colorectal cancer (ACC): A phase II study of giscad (Italian group for the study of gastrointestinal cancer).Proc. Am. Soc. Clin. Oncol. 11, 523.Google Scholar
  93. 93.
    Schmoll, H.J., Kohne-Wömpner, C.H.Y., Hiddemann, W., Rauschecker, H., Preiss, C., Balleisen, J., Lohrman, H.P., Fischer, J.T.H. and Harstrick, A. (1992) Bolus 5-fluorouracil (FU), folinic acid (FA) and alpha-2b interferon (IFN) in advanced colorectal cancer (CRC): A multicentre phase II trial.Proc. Am. Soc. Clin. Oncol. 11, 535.Google Scholar
  94. 94.
    Moore, M.J., Kaizer, L., Erlichman, C., Bunting, R., Feld, R., Fine, S., Myers, R., Thiessen, J.J. and Yuan, S. (1992) A phase II clinical and pharmacologic study of 5-fluorouracil (5FU) + leucovorin + interferon in advanced colorectal cancer.Proc. Am. Soc. Clin. Oncol. 11, 548.Google Scholar
  95. 95.
    Lembersky, B., Koff, H., Miketic, L., Posner, M., Jacobs, S. and Carr, B. (1992) Phase II trial of 5-fluorouracil (FU) leucovorin (LV) and interferon alfa-2b (IFN) in the treatment of metastatic colorectal cancer (CRC).Proc. Am. Soc. Clin. Oncol. 11, 559.Google Scholar
  96. 96.
    Kreuser, E.D., Hilgenfeld, R.U., Matthias, M., Hoksch, B., Boewer, C., Oldenkott, B., Lenk, H., Wiener, N., Schalhorn, A., Thiel, E. and Boese-Landgraf, J. (1992) Final update on a phase II trial of interferon alfa-2b with folinic acid and a 4-hour infusion of 5-fluorouracil in advanced colorectal carcinoma.Semin. Oncol. 2 (Suppl 4), 57–62.Google Scholar
  97. 97.
    Van Hazel, G.A., Buck, M. and Byrne, N.J. (1992) Phase II study of the combination of 5-fluorouracil (5FU), folinic acid (FA) and alpha interferon (IFN) in metastatic colorectal adenocarcinoma cancer (CC).Proc. Am. Soc. Clin. Oncol. 11, 594.Google Scholar
  98. 98.
    Punt, C., Burghouts, M., Croles, J. van Liessum, P., de Mulder, P. and Kamm, Y. (1993) Continuous infusion of high-dose 5-fluorouracil in combination with leucovorin and recombinant interferon-alpha-2b in patients with advanced colorectal cancer: A multicentre phase II study.Cancer 72, 2107–11.PubMedGoogle Scholar
  99. 99.
    Sobrero, A., Nobile, M.T., Guglielmi, A., Mori, A., Aschele, C., Bolli, E., Tixi, L., Gallo, L., Parodi, G.C., Bruzzi, P., Brema, F. and Rosso, R. (1992) Phase II study of 5-fluorouracil plus leucovorin and interferon alpha 2b in advanced colorectal cancer.Eur. J. Cancer 4/5, 850–2.Google Scholar
  100. 100.
    Fedeli, A., Fedeli, S.L. and Catalano, G. (1991) Double biochemical modulation of 5-fluorouracil by leucovorin and cyclic low dose interferon alpha 2b in advanced colorectal cancer patients.Ann. Oncol. 3, 489–91.Google Scholar
  101. 101.
    Grem, J.L., McAtee, N., Murphy, R.F., Balis, F.M., Steinberg, S.M., Hamilton, J.M., Sorensen, J.M., Sartor, O., Kramer, B.S., Goldstein, L.J., Gay, L.M., Caubo, K.M., Goldspiel, B. and Allegra, C.J. (1991) A pilot study of interferon alfa-2a in combination with fluorouracil plus high-dose leucovorin in metastatic gastrointestinal carcinoma.J. Clin. Oncol. 10, 1811–20.Google Scholar
  102. 102.
    Grem, J.L., Jordan, E., Robson, M.E., Binder, R.A., Hamilton, J.M., Steinberg, S.M., Arbuck, S.G., Beveridge, R.A., Kales, A.N., Miller, J.A., Weiss, R.B., McAtee, N., Chen, A., Goldspiel, B., Sover, E. and Allegra, C.J. (1993) Phase II study of fluorouracil, leucovorin and interferon alfa-2a in metastatic colorectal carcinoma.J. Clin. Oncol. 11, 1737–45.PubMedGoogle Scholar
  103. 103.
    Collins, K.D. and Stark, G.R. (1971) Aspartate transcarbamylase, interaction with the transition state analogue N-(phosphon-acetyl) L-aspartate.J. Biol. Chem. 246, 6599–605.PubMedGoogle Scholar
  104. 104.
    Hunting, D. and Henderson, J.F. (1982) Relation between ribo- and deoxyribonucleotide concentrations and biological parameters in cultured Chinese hamster ovary cells.Biochem. Pharmacol. 31, 1109–15.PubMedGoogle Scholar
  105. 105.
    Casper, E.S., Vale, K., Williams, L.J., Martin, D.S. and Young, C.W. (1983) Phase I and clinical pharmacological evaluation of biochemical modulation of 5-fluorouracil with N-(phosphonacetyl)-L-aspartic acid.Cancer Res. 43, 2324–8.PubMedGoogle Scholar
  106. 106.
    Kensler, T., Erlichman, C., Jayararam, H.N., Tyagi, A.K., Ardalan, B. and Cooney, D.A. (1980) Peripheral leukocytes as indicators of the enzymic effect of N-(Phosphonoacetyl)-L-aspartic acid on human L-aspartate transcarbamoylase (ACTase) activity.Cancer Treat. Rep. 64, 967–73.PubMedGoogle Scholar
  107. 107.
    Moore, C.E., Friedman, J., Valdivieso, M.et al. (1982) Aspartate carbamoyltransferase activity, drug concentrations and pyrimidine nucleotides in tissue from patients treated with N-(phosphonoacetyl)-L-aspartate.Biochem. Pharmacol. 31, 3317–21.PubMedGoogle Scholar
  108. 108.
    Spiegelman, S., Nayak, R., Sawyer, R., Stolfi, R. and Martin, D. (1980) Potentiation of the anti-tumor activity of 5-FU by thymidine and its correlation with the formation of (5-FU) RNA.Cancer 45, 1129–34.PubMedGoogle Scholar
  109. 109.
    Sartorelli, A.C. and Creasey, W.A. (1982) Combination chemotherapy. In: J.F. Holland and E. Frei III (eds.)Cancer Medicine, 2nd edn. pp. 720–30. Philadelphia, PA: LEA and Febiger.Google Scholar
  110. 110.
    Bedikian, A.Y., Stroehlein, J.R., Karlin, D.A., Bennetts, R.W., Bodey, G.P. and Valdivieso, M. (1981) Chemotherapy for colorectal cancer with a combination of PALA and 5-FU.Cancer Treat. Rep. 65, 747–52.PubMedGoogle Scholar
  111. 111.
    Erlichman, C., Donehower, R.C., Speyer, J.L.et al. (1982) A phase I–II trial of N-phosphonacetyl-L-aspartic acid given by intravenous infusion and 5-fluorouracil given by bolus injection. J. Natl. Cancer Inst.68, 227–31.PubMedGoogle Scholar
  112. 112.
    Meshad, M.W., Ervin, T.J., Kufe, D., Johnson, R.K., Blum, R.H. and Frei, E. (1981) Phase I trial of combination therapy with PALA and 5-FU.Cancer Treat. Rep. 65, 331–4.PubMedGoogle Scholar
  113. 113.
    O’Connell, M.J., Powis, G., Rubin, J. and Moertel, C.G. (1982) Pilot study of PALA and 5-FU in patients with advanced cancer.Cancer Treat. Rep. 66, 77–80.PubMedGoogle Scholar
  114. 114.
    Weiss, G.R., Ervin, T.J., Meshad, M.W. and Kufe, D.W. (1982) Phase II trial of combination therapy with continuous infusion PALA and bolus injection 5-FU.Cancer Treat. Rep. 66, 299–303.PubMedGoogle Scholar
  115. 115.
    Presant, C.A., Ardalan, B., Multhauf, P.et al. (1983) Continuous five-day infusion of PALA and 5-FU: A pilot phase II trial.Med. Pediatr. Oncol. 11, 162–3.PubMedGoogle Scholar
  116. 116.
    Muggia, F.M., Camacho, F.J., Kaplan, B.H., Green, M.D., Greenwald, E.S., Wernz, J.C. and Engstrom, P.F. (1987) Weekly 5-fluorouracil combined with PALA: Toxic and therapeutic effects in colorectal cancer.Cancer Treat. Rep. 71, 253–6.PubMedGoogle Scholar
  117. 117.
    Buroker, T.R., Moertel, C.G., Fleming, T.R.et al. (1985) A controlled evaluation of recent approaches to biochemical modulation or enhancement of 5-fluorouracil therapy in colorectal carcinoma.J. Clin. Oncol. 3, 1624–31.PubMedGoogle Scholar
  118. 118.
    Ardalan, B., Singh, G. and Silberman, H. (1988) A randomized phase I and II study of short term infusion of high-dose fluorouracil with or without N-(phosphonoacetyl)-L-aspartic acid in patients with advanced pancreatic and colorectal cancers.J. Clin. Oncol. 6, 1053–8.PubMedGoogle Scholar
  119. 119.
    O’Dwyer, P.J., Paul, A.R., Walczak, J.et al. (1990) Phase II study of biochemical modulation of fluorouracil by low-dose PALA in patients with colorectal cancer.J. Clin. Oncol. 8, 1497–503.PubMedGoogle Scholar
  120. 120.
    Kemeny, N., Costa, P., Conti, J.A., Seiter, K., Niedzwiecki, D., Botet, J., Martin, D., Wiseberg, J. and McCulloch, W. (1992) Phase II trial of PALA and 5-FU in metastatic colorectal carcinoma.J. Clin. Oncol. 5, 747–52.Google Scholar
  121. 121.
    Moran, R.G. and Scanion, K.L. (1991) Schedule-dependent enhancement of the cytotoxicity of fluoropyrimidines to human carcinoma cells in the presence of folinic acid.Cancer Res. 51, 4618–23.PubMedGoogle Scholar
  122. 122.
    Aschele, C., Sobrero, A., Faderan, M.A. and Bertino, J.R. (1992) Novel mechanism(s) of resistance to 5-fluorouracil in human colon cancer (HCT-8) sublines following exposure to two different clinically relevant dose schedules.Cancer Res. 52, 1855–64.PubMedGoogle Scholar
  123. 123.
    Sobrero, A.F., Aschele, C., Guglielmi, A.P., Moria, A.M., Melioli, G.G., Ross, R. and Bertino, J.R. (1993) Synergism and lack of cross-resistance between short-term and continuous exposure to fluorouracil in human adenocarcinoma cells.Natl. Cancer Inst. 85, 1937–44.Google Scholar
  124. 124.
    Sobrero, A.F., Aschele, C., Guglielmi, A.P., Moria, A.M., Mammoliti, S., Tixi, L., Bolli, E., Rosso, R. and Bertino, J.R. (1994) High activity and low toxicity of alternating bolus and continuous infusion 5-fluorouracil with schedule oriented biochemical modulation.Proc. Am. Soc. Clin. Oncol. 13, 588 (Abstract).Google Scholar
  125. 125.
    Pinedo, H.M. and Peters, G.J. (1988) 5-fluorouracil: Biochemistry and pharmacology.J. Clin. Oncol. 6, 1653–64.PubMedGoogle Scholar
  126. 126.
    Priest, D.G., Ledford, S.E. and Doig, M.T. (1980) Increased thymidylate synthetase in 5-fluorodeoxyuridine resistant cultured hepatoma cells.Biochem. Pharmacol. 29, 1549–53.PubMedGoogle Scholar
  127. 127.
    Berger, S.H., Barbour, K.W. and Berger, F.G. (1988) A naturally occuring variation in thymidylate synthase structure is associated with a reduced response to 5-fluoro-2′-deoxyuridine in a human colon tumor cell line.Mol. Pharmacol. 34, 480–4.PubMedGoogle Scholar
  128. 128.
    Berger, S.H., Jenh, C.H., Johnson, L.F.et al. (1985) Thymidylate synthase overproduction and gene amplification in fluorodeoxyuridine-resistant human cells.Mol. Pharmacol. 28, 461–7.PubMedGoogle Scholar
  129. 129.
    Van der Wilt, C.L., Pinedo, H.M., Smid, K.et al. (1992) Elevation of thymidylate synthase following 5-fluorouracil treatment is prevented by addition of leucovorin in murine colon tumors.Cancer Res. 52, 4922–8.PubMedGoogle Scholar
  130. 130.
    Clark, J.L., Berger, S.H., Mittelman, A.et al. (1987) Thymidylate synthase overproduction gene amplification in a colon tumor resistant to fluoropyrimidine chemotherapy.Cancer Treat. Rep. 71, 261–5.PubMedGoogle Scholar
  131. 131.
    Swain, S.M., Lippman, M.E., Egan, E.F.et al. (1989) Fluorouracil and high-dose leucovorin in previously treated patients with metastatic breast cancer.J. Clin. Oncol. 7, 890–9.PubMedGoogle Scholar
  132. 132.
    Sobrero, A.F., Aschele, C., Guglielmi, A.P.et al. (1993) Synergism and lack of cross-resistance between short-term and continuous exposure to fluorouracil in human colon adenocarcinoma cells.J. Natl. Cancer Inst. 85, 1937–44.PubMedGoogle Scholar
  133. 133.
    Johnston, P.G., Drake, J.C., Trepel, J. and Allegra, C.J. (1992) Immunological quantitation of thymidylate synthase using the monoclonal antibody TS 106 in 5-fluorouracil-sensitive and resistance human cancer cell lines.Cancer Res. 52, 4306–12.PubMedGoogle Scholar
  134. 134.
    Johnston, P.G., Fisher, E.R., Rockette, H.E., Fisher, B., Wolmark, N., Allegra, C.J., Drake, J.C. and Chabner, B.A. (1994) The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer.J. Clin. Oncol. 12, 2640–7.PubMedGoogle Scholar
  135. 135.
    Nord, L.D., Stolfi, R.L. and Martin, D.S. (1993) Biochemical modulation of 5-fluorouracil with leucovorin or delayed uridine rescue.Biochem. Pharmacol. 44, 2543–9.Google Scholar
  136. 136.
    Spears, C.P., Gustavsson, B.G., Berne, M., Frösing, R., Bernstein, L. and Hayes, A. (1988) Mechanism of innate resistance to thymidylate inhibition after 5-fluorouracil.Cancer Res. 48, 5894–900.PubMedGoogle Scholar
  137. 137.
    Horikoshi, T., Danenberg, K.D., Stadlbauer, T.H.W., Volkenandt, M., Shea, L.C.C., Aigner, K., Gustavsson, B., Leichman, L., Frösing, R., Ray, M., Gibson, N.W., Spears, C.P. and Danenberg, P.V. (1992) Quantitation of thymidylate synthase, dihydrofolate reductase, and DT-diaphorase gene expression in human tumors using the polymerase chain reaction.Cancer Res. 52, 108–16.PubMedGoogle Scholar

Copyright information

© Humana Press Inc. 1995

Authors and Affiliations

  • Peter Ragnhammar
    • 1
  • Henric Blomgren
    • 1
  1. 1.Department of Oncology (Radiumhemmet)Karolinska HospitalStockholmSweden

Personalised recommendations